329 related articles for article (PubMed ID: 21605234)
1. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
2. Organ transplantation and skin cancer: basic problems and new perspectives.
Hofbauer GF; Bouwes Bavinck JN; Euvrard S
Exp Dermatol; 2010 Jun; 19(6):473-82. PubMed ID: 20482618
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin.
Euvrard S; Ulrich C; Lefrancois N
Dermatol Surg; 2004 Apr; 30(4 Pt 2):628-33. PubMed ID: 15061847
[TBL] [Abstract][Full Text] [Related]
5. Systemic strategies for chemoprevention of skin cancers in transplant recipients.
Kovach BT; Sams HH; Stasko T
Clin Transplant; 2005 Dec; 19(6):726-34. PubMed ID: 16313317
[TBL] [Abstract][Full Text] [Related]
6. Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer.
Karia PS; Azzi JR; Heher EC; Hills VM; Schmults CD
JAMA Dermatol; 2016 May; 152(5):533-40. PubMed ID: 26792250
[TBL] [Abstract][Full Text] [Related]
7. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
8. [Swiss clinical practice guidelines for skin cancer in organ transplant recipients].
Lapointe AK; Hofbauer G; Anliker M; Arnold A; Binet I; Hunger R; Kempf W; Pascual M; Pelloni F; Serra A; Laffitte E
Rev Med Suisse; 2010 Apr; 6(246):854-9. PubMed ID: 20455382
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment.
Kim C; Cheng J; Colegio OR
Semin Oncol; 2016 Jun; 43(3):390-4. PubMed ID: 27178693
[TBL] [Abstract][Full Text] [Related]
10. The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.
Schaper-Gerhardt K; Walter A; Schmitz-Rode C; Satzger I; Gutzmer R
J Dermatol Sci; 2018 Nov; 92(2):172-180. PubMed ID: 30220530
[TBL] [Abstract][Full Text] [Related]
11. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study.
Harwood CA; Leedham-Green M; Leigh IM; Proby CM
Arch Dermatol; 2005 Apr; 141(4):456-64. PubMed ID: 15837863
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract][Full Text] [Related]
13. The relative effects of different systemic immunosuppressives on skin cancer development in organ transplant patients.
Durando B; Reichel J
Dermatol Ther; 2005; 18(1):1-11. PubMed ID: 15842607
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach.
Ritchie SA; Patel MJ; Miller SJ
Dermatol Surg; 2012 Oct; 38(10):1604-21. PubMed ID: 22646842
[TBL] [Abstract][Full Text] [Related]
15. Reducing skin malignancy risk in organ transplant recipients.
Francis S; Berg D
Skin Therapy Lett; 2013 Jan; 18(1):1-3. PubMed ID: 23474655
[TBL] [Abstract][Full Text] [Related]
16. [Immunosuppressive drugs and the development of skin cancer after organ transplantation].
Gjersvik P; Helsing P; Holdaas H; Bergan S
Tidsskr Nor Laegeforen; 2012 Oct; 132(18):2064-8. PubMed ID: 23038197
[TBL] [Abstract][Full Text] [Related]
17. Skin cancer in liver transplant recipients.
Otley CC; Pittelkow MR
Liver Transpl; 2000 May; 6(3):253-62. PubMed ID: 10827224
[TBL] [Abstract][Full Text] [Related]
18. No association between infections, HLA type and other transplant-related factors and risk of cutaneous squamous cell carcinoma in solid organ transplant recipients.
Ingvar Å; Ekström Smedby K; Lindelöf B; Fernberg P; Bellocco R; Tufveson G; Höglund P; Adami J
Acta Derm Venereol; 2012 Nov; 92(6):609-14. PubMed ID: 22293782
[TBL] [Abstract][Full Text] [Related]
19. Sun protection attitudes and behaviors of solid-organ transplant recipients.
Robinson JK; Rigel DS
Dermatol Surg; 2004 Apr; 30(4 Pt 2):610-5. PubMed ID: 15061844
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single- and multicenter retrospective studies from 2006 to 2010.
Mudigonda T; Levender MM; O'Neill JL; West CE; Pearce DJ; Feldman SR
Dermatol Surg; 2013 Mar; 39(3 Pt 1):345-64. PubMed ID: 23190408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
